EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy

Published: 14 July 2023| Version 1 | DOI: 10.17632/p687n8sw3t.1
Contributors:
, Oltin Pop, Eftychia Chatziioannou, Tobias Sinnberg, Heike Niessner, Jing Zhao, Sandra Stephanie Ring, Markus Joerger, Christopher Schroeder, Sorin Armeanu-Ebinger, Antonio Cozzio, Ulrike Leiter, Ioannis Thomas, Wolfram Jochum, Claus Garbe, Stephan Forchhammer, Mitchell Levesque, Johanna Mangana@usz.ch, Michael Hölzel, Reinhard Dummer, Christian Martin Schürch, Andrea Forschner, Lukas Flatz

Description

Suppementary Data for manuscript: Amaral T, Pop OT, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring SS, Joerger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch CM, Forschner A, Flatz L. EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. JAAD 2023

Files

Categories

Melanoma, Adjuvant Therapy, Prognostic Factor, Immune Checkpoint Blockade

Licence